Krystal Biotech (KRYS) Long-Term Investments (2019 - 2026)
Krystal Biotech (KRYS) posted quarterly Long-Term Investments of $257.3 million for Q2 2026, up 85.36% year-over-year from $138.8 million in Q2 2025, and up 32.98% on a QoQ basis from $193.5 million in Q1 2026.
Krystal Biotech (KRYS) Long-Term Investments (2019 - 2026) Analysis & Trends
Krystal Biotech has reported Long-Term Investments for 7 years, with the latest figure at $257.3 million in Q2 2026.
- Long-Term Investments for Q2 2026 came in at $257.3 million, up 85.36% year-over-year; the trailing twelve-month figure through Jun 2026 was $257.3 million (up 85.36% YoY), and the FY2025 annual result was $128.1 million, down 15.81% from the prior year.
- Long-Term Investments improved to $257.3 million in Q2 2026, from $193.5 million in the prior quarter.
- Over five years, Long-Term Investments peaked at $257.3 million in Q2 2026 and troughed at $4.6 million in Q4 2022.
- A 5-year average of $89.2 million and a median of $76.6 million in 2024 frame the typical range for Long-Term Investments.
- The widest annual swing landed in 2022, when Long-Term Investments plunged 92.82%; it then soared 1537.67% in 2024.
- A 5-year view of Long-Term Investments shows it stood at $4.6 million in 2022, then surged by 1240.71% to $62.0 million in 2023, then soared by 145.53% to $152.1 million in 2024, then dropped by 15.81% to $128.1 million in 2025, then surged by 100.91% to $257.3 million in 2026.
- Per Business Quant data, the three most recent Long-Term Investments figures were $257.3 million in Q2 2026, $193.5 million in Q1 2026, and $128.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 372.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.17 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Krystal Biotech | 9.83 Bn | 8.99 Bn | 112.79 Mn | 257.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 257.29 Mn |
| Mar 31, 2026 | 193.49 Mn |
| Dec 31, 2025 | 128.07 Mn |
| Sep 30, 2025 | 133.11 Mn |
| Jun 30, 2025 | 138.81 Mn |
| Mar 31, 2025 | 148.47 Mn |
| Dec 31, 2024 | 152.11 Mn |
| Sep 30, 2024 | 105.89 Mn |
| Jun 30, 2024 | 69.29 Mn |
| Mar 31, 2024 | 84.00 Mn |
| Dec 31, 2023 | 61.95 Mn |
| Sep 30, 2023 | 36.55 Mn |
| Jun 30, 2023 | 28.41 Mn |
| Mar 31, 2023 | 5.13 Mn |
| Dec 31, 2022 | 4.62 Mn |
| Sep 30, 2022 | 12.56 Mn |
| Jun 30, 2022 | 12.90 Mn |
| Mar 31, 2022 | 33.34 Mn |
| Dec 31, 2021 | 64.37 Mn |
| Sep 30, 2021 | 19.24 Mn |